Loading
A whole-genome blood test that corrects errors read by read detected tumour DNA at about ten parts per million and predicted relapse after bowel cancer surgery.
AccuScan is a cell-free DNA whole-genome sequencing technology with error correction at the level of single reads, with an error rate of 4.2 x 10^-7, about two orders of magnitude lower than a read-centric de-noising method. Applied to residual disease it showed analytical sensitivity down to 10^-6 circulating variant allele frequency at 99 per cent sample-level specificity; 90 per cent landmark sensitivity and 100 per cent specificity for relapse in colorectal cancer within six weeks of surgery; 67 per cent sensitivity and 100 per cent specificity in oesophageal cancer within a week of surgery; and ctDNA dynamics consistent with outcome in melanoma on immunotherapy.
Whole-genome methods without a personalised panel can approach ten parts per million. Below that, the published replicates thin out.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Whole-exome & whole-genome sequencing, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/